INOVIO Pharmaceuticals Reports $6M Net Loss, Focuses on FDA Review for INO-3107

INOVIO Pharmaceuticals, Inc. reported a net loss of $6.0 million for the three months ended June 30, 2026, a significant decrease from the $23.5 million loss recorded in the same period of the previous year. For the six months ended June 30, 2026, the company experienced a net loss of $25.7 million, down from $43.2 million in the prior year. The reduction in losses is attributed to decreased operating expenses, particularly in research and development, which fell to $10.8 million from $14.5 million year-over-year for the quarter, and to $24.9 million from $30.6 million for the six-month period. The company did not generate any revenue during the current quarter, compared to $65,000 from collaborative arrangements in the same quarter of 2025.

INOVIO's total assets decreased to $49.4 million as of June 30, 2026, down from $74.3 million at the end of 2025. The decline in assets was primarily due to a reduction in cash and cash equivalents, which fell to $31.5 million from $44.3 million. The company reported a working capital deficit of $2,000, indicating financial strain as it continues to seek additional capital to fund its operations. The accumulated deficit increased to $1.84 billion, reflecting ongoing losses since the company's inception.

Strategically, INOVIO is focused on advancing its lead product candidate, INO-3107, which is under review by the FDA for accelerated approval as a treatment for recurrent respiratory papillomatosis (RRP). The company has engaged Syneos Health to assist with commercialization efforts in anticipation of a potential approval. INOVIO has also entered into collaborations with various partners, including Akeso Inc. for the development of INO-5412 in glioblastoma treatment, and Coherus BioSciences for INO-3112 targeting oropharyngeal squamous cell carcinoma.

Operationally, INOVIO's employee headcount remains limited, and the company has no in-house sales team, which may hinder its ability to generate product revenues if its candidates receive regulatory approval. The company is also facing significant competition in the biotechnology sector, particularly following the approval of PAPZIMEOS for RRP treatment, which could impact INOVIO's market share. The company has indicated that it will need substantial additional capital to continue its research and development activities, and there is substantial doubt about its ability to continue as a going concern beyond the first quarter of 2027 without securing further financing.